![](https://static.biospace.com/dims4/default/69d8353/2147483647/strip/true/crop/360x180+0+0/resize/200x100!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Flegacy%2FBioSpace-Assets%2F42F52CB2-0087-4679-AA93-D74FEBCDC172.png)
Olema Oncology
NEWS
A lot of attention at JPM was focused on the cancer space. Executives from Olema Oncology and Cyclacel spoke with BioSpace about their plans for 2024 and why biotech’s kickoff conference is important to them.
FDA Weekly Review looks at the FDA’s actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.
Olema president and CEO Sean Bohen spoke with BioSpace about why he believes his company’s approach with a SERD and ER antagonist can successfully treat an advanced form of breast cancer.
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
JOBS
IN THE PRESS